title: Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.
abstract: Cancer is one of the most important health problems because many cases are difficult to prevent. Cancer still has unknown mechanisms of pathogenesis, and its capacity to produce temporary or permanent damage, besides death, is very high. Although many anticancer therapies are available, finding a cure for cancer continues to be a difficult task. Thus, many efforts have been made to develop more effective treatments, such as immunotherapy based on a new class of tumor-specific products that are produced using recombinant DNA technology. These recombinant products are used with the main objectives of killing the tumor and stimulating immune cells to respond to the cancer cells. The principal recombinant products in anticancer therapy are immunostimulants, vaccines, antibodies, immunotoxins and fusion proteins. This review focuses on the general aspects of these genetically engineered products, their clinical performance, current advances and future prospects for this type of anticancer therapy.
authors: Curso de Medicina; Universidade Federal do Tocantins; Palmas, Brazil.
authors: Maria-Cristina S
authors: MC
authors: Pranchevicius
authors: Thiessa R
authors: TR
authors: Vieira
mesh_terms: D000276:Adjuvants, Immunologic / Q000096:biosynthesis / Q000627:therapeutic use; D000906:Antibodies / Q000737:chemistry / Q000627:therapeutic use; D001427:Bacterial Toxins / Q000096:biosynthesis / Q000627:therapeutic use; D057005:Bioengineering / Q000379:methods*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D000922:Immunotoxins / Q000737:chemistry / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D001427:Bacterial Toxins; D019496:Cancer Vaccines; D018796:Immunoconjugates; D000922:Immunotoxins; D011993:Recombinant Fusion Proteins
keywords: antibodies; cancer vaccines; fusion proteins; immunostimulants; immunotherapy; immunotoxins; recombinant drugs
references: J Clin Oncol. 2008 Apr 10;26(11):1774-7
references: 18398141
references: Expert Rev Anticancer Ther. 2003 Dec;3(6):767-79
references: 14686699
references: Cancer Biother Radiopharm. 2011 Feb;26(1):1-64
references: 21355777
references: Biotechnol J. 2011 Jan;6(1):16-27
references: 21170983
references: Drug Discov Today. 2011 Jun;16(11-12):495-503
references: 21511052
references: Methods Mol Biol. 2012;907:713-27
references: 22907382
references: Br Med Bull. 2012;104:41-59
references: 23118261
references: Clin Dev Immunol. 2010;2010:697158
references: 20936120
references: N Biotechnol. 2011 Sep;28(5):518-29
references: 21473941
references: Clin Colorectal Cancer. 2013 Jun;12(2):73-85
references: 23102896
references: J Manag Care Pharm. 2010 Apr;16(3):217-30
references: 20331326
references: Cancer. 2009 Aug 15;115(16):3670-9
references: 19536890
references: Immunol Rev. 2008 Apr;222:9-27
references: 18363992
references: Expert Rev Vaccines. 2011 Jun;10(6):713-5
references: 21692693
references: Ann N Y Acad Sci. 2010 Apr;1194:169-78
references: 20536466
references: Hum Vaccin. 2011 Mar;7(3):313-21
references: 21346417
references: Hum Vaccin. 2009 Oct;5(10):671-89
references: 19684468
references: N Engl J Med. 2006 Dec 14;355(24):2542-50
references: 17167137
references: J Clin Oncol. 2007 Apr 20;25(12):1539-44
references: 17442997
references: Trends Biotechnol. 2003 Nov;21(11):484-90
references: 14573361
references: Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2823-6
references: 21893546
references: J Clin Oncol. 2001 Jan 15;19(2):376-88
references: 11208829
references: Adv Cancer Res. 2006;95:115-45
references: 16860657
references: Oncologist. 2007 May;12(5):577-83
references: 17522246
references: Cancer Immun. 2012;12:14
references: 22896759
references: Nat Rev Drug Discov. 2010 Apr;9(4):325-38
references: 20305665
references: J Biomed Biotechnol. 2010;2010:
references: 20706612
references: N Engl J Med. 2007 Dec 27;357(26):2666-76
references: 18160686
references: Immunol Res. 2002;25(2):177-91
references: 11999171
references: Cancer Genomics Proteomics. 2012 Nov;9(6):357-72
references: 23162075
references: Immunotherapy. 2011 Nov;3(11):1317-40
references: 22053884
references: Cancer Manag Res. 2012;4:215-21
references: 22904643
references: Curr Opin Microbiol. 2012 Jun;15(3):300-9
references: 22647353
references: J Natl Cancer Inst. 2012 Apr 18;104(8):599-613
references: 22395641
references: J Clin Oncol. 2010 Apr 10;28(11):1870-7
references: 20212249
references: Cancer J. 2012 Sep-Oct;18(5):450-6
references: 23006951
references: J Immunol. 2011 Feb 1;186(3):1325-31
references: 21248270
references: Lancet Oncol. 2012 Jan;13(1):25-32
references: 22153890
references: Biotechnol Healthc. 2011 Winter;8(4):25-7
references: 22479231
references: J Biomed Sci. 2010 Mar 23;17(1):21
references: 20331869
references: Nat Rev Immunol. 2010 May;10(5):317-27
references: 20414205
references: J Clin Oncol. 2005 Jun 1;23(16):3706-12
references: 15867200
references: Cancer Treat Rev. 2012 Aug;38(5):484-93
references: 22264850
references: FEMS Microbiol Rev. 2000 Jan;24(1):9-20
references: 10640596
references: Breast J. 2003 Nov-Dec;9(6):452-62
references: 14616939
references: Nature. 2011 Dec 21;480(7378):480-9
references: 22193102
references: Nat Rev Immunol. 2010 May;10(5):301-16
references: 20414204
references: Trends Mol Med. 2002;8(4 Suppl):S19-26
references: 11927283
references: Pharmacol Ther. 2012 Jul;135(1):44-53
references: 22484806
references: AAPS J. 2006 Aug 18;8(3):E532-51
references: 17025272
references: Blood. 2001 Sep 1;98(5):1326-31
references: 11520778
references: Semin Oncol. 2003 Dec;30(6 Suppl 17):1-5
references: 14710396
references: J Clin Oncol. 1998 Aug;16(8):2825-33
references: 9704735
references: Plant Biotechnol J. 2010 Jun;8(5):529-63
references: 20132515
references: N Engl J Med. 2004 Jul 22;351(4):337-45
references: 15269313
references: Indian J Med Res. 2009 Sep;130(3):327-33
references: 19901442
references: Curr Pharm Biotechnol. 2011 Feb 1;12(2):268-74
references: 21050165
references: Methods Mol Biol. 2009;525:1-27, xiii
references: 19252861
references: Mol Cancer. 2011 Jan 07;10:3
references: 21211062
references: Nat Rev Drug Discov. 2010 Oct;9(10):767-74
references: 20811384